TICKERNERD
Menu
AMLXAMLXHealthcare · Drug Manufacturers - Specialty & Generic

AMLX Stock Forecast: Amylyx Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$22
−3.78% on the day

The 11 Wall Street analysts covering Amylyx Pharmaceuticals, Inc. hold a median 12-month price target of $27 — +24.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 14 Aug 2026 — in the upper half.

Market cap
$2.6B
Ticker Nerd rank
54 / 100
Median analyst target
$27
Analysts covering
11
Total return, dividends reinvested
1W
−5.2%
1M
+18.8%
YTD
+79.1%
1Y
+157.2%
From 52W high
−10.6%
From 52W low
+176.6%
$8
$24
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AMLX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Amylyx Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Aug 2026
54 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
94
Growth
88
Value
66
Volatility
50
Accruals
48
Issuance
40
Size
35
Quality
34
Revisions
33

Momentum (94): The shares have been drifting up relative to others.

Revisions (33): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AMLX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AMLX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40Oct 25Jan 26Apr 26Jul 26AMLXHigh $40Median $27Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts
10 Buy1 Hold0 Sell
Low $20Median $27High $40

The green dot is the last close — the median target sits +24.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
3 Aug 2026CitigroupMaintainsBuy$20 → $26
20 July 2026MizuhoMaintainsOutperform—
20 July 2026MizuhoMaintainsOutperform$21 → $24
25 June 2026GuggenheimMaintainsBuy$30 → $40
25 June 2026GuggenheimMaintainsBuy—
28 Apr 2026MizuhoMaintainsOutperform—
25 Mar 2026HC Wainwright & Co.ReiteratesBuy—
19 Mar 2026GuggenheimMaintainsBuy—
4 Mar 2026HC Wainwright & Co.MaintainsBuy—
3 Mar 2026StifelInitiatesBuy—
20 Feb 2026B of A SecuritiesMaintainsBuy—
10 Feb 2026HC Wainwright & Co.MaintainsBuy—
7 Nov 2025HC Wainwright & Co.MaintainsBuy—
17 Oct 2025CitigroupMaintainsBuy—
16 Oct 2025BairdMaintainsOutperform—
3 Oct 2025B of A SecuritiesMaintainsBuy—
16 Sept 2025Goldman SachsMaintainsBuy—
15 Sept 2025GuggenheimMaintainsBuy—
28 Aug 2025B of A SecuritiesMaintainsBuy—
10 July 2025Goldman SachsReinstatesBuy$10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AMLX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

AMLX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Amylyx Pharmaceuticals, Inc. (AMLX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.5×

Cheaper than 69% of US stocks

Price / sales
—
Price / book
11.0×

Cheaper than 10% of US stocks

EV / EBITDA
−14.6×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 33% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−74.7%

Higher than 16% of US stocks

Return on assets
−44.1%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

AMLX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
AMLXAmylyx Pharmaceuticals, Inc.$2.6B
54
BHCBausch Health Cos., Inc.$2.4B
97
BCRXBioCryst Pharmaceuticals, Inc.$2.4B
86
PBHPrestige Consumer Healthcare, Inc.$2.5B
58
RGCRegencell Bioscience Holdings Ltd.$2.7B
4
SUPNSupernus Pharmaceuticals, Inc.$2.8B
84
TRLVTrulieve Cannabis Corp.$1.9B
85

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Amylyx Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AMLX news & analysis

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

Zacks Investment Research · 11 Aug 2026neutral

Amylyx Pharmaceuticals was named by Zacks Investment Research as one of four biotech stocks with major second-half pipeline catalysts this year, including potential FDA decisions and late-stage data readouts in 2026.

Why it matters — An AMLX watcher would care because the article signals that upcoming FDA decisions and late-stage trial results in the second half could be significant catalysts for the company's stock performance.

Amylyx Pharmaceuticals: Avexitide Defines The Endocrine Rebuild

Seeking Alpha · 7 Aug 2026positive

Seeking Alpha reports that Amylyx Pharmaceuticals is shifting focus from its ALS legacy to become a late-stage endocrine company, with avexitide as its lead asset. The company's $250.8M cash runway extends into 2028, supporting the LUCIDITY Phase 3 readout, regulatory submission, and a potential 2027 launch, with topline results expected in late August or early September 2026.

Why it matters — AMLX watchers would care because a positive avexitide readout could position the company in an unserved post-bariatric hypoglycemia market with a cash runway that avoids near-term financing risk.

Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha published the Q2 2026 earnings call transcript for Amylyx Pharmaceuticals, Inc. (AMLX), covering the company's quarterly earnings conference call.

Why it matters — An AMLX watcher would care because the transcript provides the full remarks and detail from company management during the Q2 2026 earnings call.

Amylyx Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026neutral

Amylyx Pharmaceuticals announced that its pivotal Phase III LUCIDITY trial of avexitide for post-bariatric hypoglycemia has completed final patient visits. Top-line data are expected in late August or early September.

Why it matters — The upcoming top-line results from the LUCIDITY trial represent a key near-term binary event for the avexitide program that AMLX watchers would follow.

Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results

Business Wire · 6 Aug 2026neutral

Amylyx Pharmaceuticals announced the release of its financial results for the second quarter of 2026. The announcement was made via a press release from the company's headquarters in Cambridge, Massachusetts.

Why it matters — AMLX watchers would care because the quarterly financial results provide an update on the company's performance and financial standing.

FAQ

Frequently asked questions about AMLX stock

What is the AMLX stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Amylyx Pharmaceuticals, Inc. have a median 12-month price target of $27, with estimates ranging from $20 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AMLX stock a buy right now?

Of the 11 analysts covering Amylyx Pharmaceuticals, Inc., 10 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Amylyx Pharmaceuticals, Inc. 54 out of 100 across roughly 4,600 US stocks as at 14 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AMLX?

As at 14 Aug 2026, Amylyx Pharmaceuticals, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).

Will AMLX stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +24.8% from the last close, and Ticker Nerd's factor model ranks Amylyx Pharmaceuticals, Inc. 54 out of 100 as at 14 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AMLX stock forecast for 2030?

No analyst covering Amylyx Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMLX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $40 over the next 12 months.

How has AMLX stock performed over the past year?

Amylyx Pharmaceuticals, Inc. returned +157.2% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Amylyx Pharmaceuticals, Inc. do?

Amylyx Pharmaceuticals, Inc. Common Stock represents ownership in a clinical-stage biopharmaceutical company dedicated to developing investigational therapies for neurodegenerative diseases and endocrine conditions.

What is the latest news on AMLX?

The most recent item we track (Zacks Investment Research, 11 Aug 2026): "4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year". Amylyx Pharmaceuticals was named by Zacks Investment Research as one of four biotech stocks with major second-half pipeline catalysts this year, including potential FDA decisions and late-stage data readouts in 2026.

Company

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. Common Stock represents ownership in a clinical-stage biopharmaceutical company dedicated to developing investigational therapies for neurodegenerative diseases and endocrine conditions. The company focuses on advancing its pipeline, including avexitide, a first-in-class GLP-1 receptor antagonist in Phase 3 trials for post-bariatric hypoglycemia and congenital hyperinsulinism; AMX0035, an oral fixed-dose combination of sodium phenylbutyrate and taurursodiol under investigation for Wolfram syndrome; AMX0114 in Phase 1 for amyotrophic lateral sclerosis; and AMX0318, a long-acting GLP-1 receptor antagonist candidate for post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals targets unmet needs in conditions like progressive supranuclear palsy, ALS, and endocrine disorders through clinical trials emphasizing safety, tolerability, and efficacy data. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company operates globally with subsidiaries supporting its research and development efforts in these critical therapeutic areas.

CEO Mr. Joshua B. Cohen · 136 employees · United States · https://amylyx.com